Abstract:An ongoing apocalyptic outbreak of a new virus causing pneumonia-like clusters in Wuhan city, China, has gleamed the world. The outbreak, confirmed on the New Year's Eve 2020, has known no boundaries since then. The number has surpassed that of Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS), and is uninterruptedly escalating. Being an RNA virus, it has a propensity to mutate due to the low proofreading capacity of RNA-dependent RNA polymerase. Step-wise mutations have led to the gradual spillover of virus and after crossing the inter-species interface, the virus has adapted itself for a stable human-to-human transmission. The disease caused by severe acute respiratory syndrome coronavirus (CoV)-2 (SARS-CoV-2) can prove deadlier if the so-called 'super-spreading events' emerge with time. Recent research has shown the maximum homology of 99% of SARS-CoV-2 to pangolins associated coronavirus, owing to which these can serve as potential intermediate host. India is responding swiftly to the emergency situation, and the whole of the country is under lockdown since 25 March 2020, to ensure social distancing. All the international flights are padlocked and the travellers are being screened at airports and seaports via thermal sensors, and quarantine for a period of 14 days is recommended. Three hundred and forty-five patients across the country tested positive with six fatalities as of 22 March 2020. No specific anti-CoV drugs are currently available. Patients are being treated with protease drugs are inhibitors, remdesivir, chloroquine, angiotensin-converting enzyme 2 inhibitors, ivermectin, sarilumab and tocilizumab, though none of these is Food and Drug Administration approved and are undergoing trials. Preventive measures such as social distancing, quarantine, cough etiquettes, proper hand washing, cleaning and decontaminating the surfaces are the mainstay for curbing the transmission of this virus. The present review highlights the update of novel SARS-CoV-2 in context to the Indian scenario.

Pathogenicity,prevention and control of coronaviruses

2019 Novel Coronavirus (2019-Ncov) and 2019-Ncov Pneumonia

A Novel Coronavirus 2019 Linked with Pneumonia in China: Current Status and Future Prospects

Identification of a novel coronavirus and the landscape of prevention and control of emerging infectious diseases

2019 Novel Coronavirus of Pneumonia in Wuhan, China: Emerging Attack and Management Strategies

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses

Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China

HISTORY AND RECENT PROGRESS IN CORONAVIRUS DISCOVERY

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

Better understanding and control of new coronavirus infection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Pathogenic Mechanisms, Antiviral Drugs, and New Vaccines

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

A new coronavirus associated with human respiratory disease in China

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Novel 2019-coronavirus on new year's Eve

Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): from Bench to Bedside

A Novel Coronavirus from Patients with Pneumonia in China, 2019